Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

About Intensity Therapeutics

 

The Company

 

Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to greatly extend the lives of cancer patients.  Our lead product, INT230-6, is currently in human clinical testing to treat refractory solid tumor cancers.   

 

The Company was founded in 2012 with the understanding that late stage solid cancer consists of well-defined visible tumors and unseen micro-metastases.  Cancer is thus both a regional and a systemic disease – with different properties.  To have an effective treatment against cancer one must destroy both the existing large observable tumors as well as the unseen cell-based micrometastases.  Intensity Therapeutics was thus ofounded to develop a new approach to treat both the macro and the micro aspects of the disease.  Our DfuseRxSM platform creates novel formulations of proven anti-cancer agents.  The products have high diffusion and dispersion properties when injected directly into tumors.  Our products directly kill the injected tumors; this results in the creation of antigenic sites that stimulates an adaptive immune response.  The immune response helps to destroy or regress the injected tumor and eliminates secondary tumors and micrometastases as well.  The Company demonstrated complete regression (CR) of large tumors and small metastases in mice using the technology.  Animals that had a CR became fully resistant to re-inoculation of the same cancer throughout their lives.  

 

The Management

 

Founder and CEO

Lewis H. Bender

 

 

Prior to founding Intensity Therapeutics, from January 2008 until 2012 Mr. Bender was the CEO of Interleukin Genetics, a personalized medicine company.  At Interleukin Mr. Bender successfully restructured the Company, increased sales eight fold, developed a new genetic-based testing platform and partnered with a large insurance provider to initiate studies leading to reimbursement of the Company’s lead product.  Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December of 2007 Mr. Bender held positions as; Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. During his career Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements.  Mr. Bender has over 22 years of biotech and pharmaceutical experience having led teams taking products from discovery to Phase III for compounds using novel drug delivery techniques.  In addition, Mr. Bender has been successful in raising (or helping to raise) capital with institutional investors using several vehicles such as registered direct placements, PIPES, S-3 & S-1 filings, and convertible debt.  Most recently for Intensity Therapeutics he has raised approximately $2,200,000 in capital with investors.

Mr. Bender has both a S.B. and S.M. in Chemical Engineering from MIT, an MBA from UPENN’s Wharton School, and an MA in International studies also from UPENN. He spent several years living in Switzerland and speaks French, German and Swiss-German dialect.

 

Vice President and Chief Medical Officer
Ian B. Walters, MD

 


Dr. Walters has over 15 years of oncology/immunology drug development experience. Prior to joining Intensity Therapeutics Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led clinical research and matrix development teams. During his tenure there he contributed to the development of multiple immuno-oncology products (Yervoy® and Nivolimumab (anti-PD-1)), as well as the licensing and partnering strategy for other immuno-oncologic agents. Dr. Walters has worked in multiple biotech companies on corporate development, translational medicine, clinical development and medical affairs including Millennium Pharmaceuticals. Dr. Walters also has been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.


 

Senior Vice President

Robert Cooke

 

 

Robert Cooke is currently Senior Vice President.  Over his 30-year career, Bob has developed a track record for driving growth through technology innovation in product, technology and executive leadership roles within the healthcare informatics field. He is currently a Vice President at National Decision Support Company, and has held executive leadership roles at Agfa Healthcare and Fujifilm Medical Systems. He is currently a part time staff member of the company.

 

Scientific Advisors

 

Douglas Hanahan, Ph.D. École Polytechnique Fédérale de Lausanne (EPFL)
Dr. Hanahan is a full professor at the Swiss Federal Institute of Technology Lausanne (EPFL). In addition, Dr. Hanahan is director of the Swiss Institute for Experimental Cancer Research (ISREC), part of EPFL; and is vice-director of the new multi-institutional Swiss Cancer Center Lausanne. He received a Ph.D. in biophysics from Harvard, where he was a Harvard Junior Fellow. As a graduate student and as a faculty member at Cold Spring Harbor Laboratory, NY, he developed innovative models for studying human cancer. Dr. Hanahan continued this work when he joined the Department of Biochemistry and Biophysics and Hormone Research at the University of California, San Francisco, CA, USA in 1988. He became head of ISREC in 2009. Dr. Hanahan’s accomplishments in the field of oncology and the tumor microenvironment have been recognized by his election to several honor societies, such as the American Academy of Arts & Sciences (2007), the Institute of Medicine of the US National Academies (2008), the US National Academy of Science (2009), and the European Molecular Biology Organization (2010). Dr. Hanahan’s paper, “The Hallmarks of Cancer," which he co-authored with Robert Weinberg and published in the journal Cell in January 2000, is one of the seminal papers in the history of cancer research, and one of Cell's most cited articles.


Riccardo Lencioni, MD, FSIR, EBIR, (University of Miami)
Dr. Riccardo Lencioni is professor of clinical radiology at the University of Miami Miller School of Medicine and director of the Interventional Oncology Research Group. Previously Dr. Lencioni was professor and director of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Pisa, Italy. He is the founder of the International Liver Cancer Association (ILCA) and served as the ILCA executive secretary. Dr. Lencioni has also served as chairman of the World Conference of Interventional Oncology, a network of interventional oncologists dedicated to the development of treatment approaches based on imaging, such as intratumoral delivery. He has been involved in the development of recommendations for the research and clinical management of hepatocellular carcinoma, and recently co-authored the white papers, “Design and Endpoints in Clinical Trials in Hepatocellular Carcinoma” (2008), “Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma” (2010), and “EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma” (2012). Riccardo Lencioni has published 190 articles in peer-reviewed international journals and 61 textbook chapters, and is the editor of nine books.


Mario Sznol, MD: Yale University – Smilow Cancer Center, New Haven

Dr. Sznol is currently professor of internal medicine at Yale University School of Medicine, co-director of the Yale Melanoma Program, and co-director of Yale SPORE in Skin Cancer. He is an investigator in several clinical trials at the Yale Cancer Center, including those focusing on immunotherapy and novel agents. Dr. Sznol has an international reputation in cancer drug development with expertise in cancer immunotherapy and the treatment of patients with melanoma and renal cell carcinoma. Dr. Sznol received his undergraduate degree from Rice University, trained in internal medicine and Baylor College of Medicine in Houston, Texas, and completed a medical oncology fellowship in the Department of Neoplastic Diseases in Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI), and was head of the BES from 1994-1999.

 

Collaborators


National Cancer Institute
Jay Berzofsky, MD, PhD - Center for Cancer Research NIH; Chief of the Vaccine Branch
Masaki Terabe, PhD - Center for Cancer Research NIH and National Cancer Institute

 

Toxicology
Chris J. Viau, PhD, DABT - is President of CJV Toxicology, LLC and a member of PharmaDirections, Inc.  Dr. Viau has twenty-nine years of applied technical, managerial and leadership expertise in toxicology, safety pharmacology, drug metabolism, pharmacokinetics, and product development across multiple therapeutic areas.  He previous has worked at Sunovion Pharmaceuticals (formerly Sepracor), and Hoechst-Marion Roussel (currently part of Sanofi-Aventis).

 

Contact Us


Intensity Therapeutics, Inc.
8 Wright Street, Suite 107
Westport, CT 06880


Tel. (203) 682-2434
Fax (203) 664-1051


info@intensitytherapeutics.com

 

Click here for career inquiries

Who we are


Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.

 

Click here for inquiries

News